Phenotypeca is delighted to announce a positive first-quarter result in the Innovate UK funded project, developing next-generation baker’s yeast production strains for Invizius’ novel H-Guard coating for dialysis membranes. These will be capable of preventing, at source, the blood’s foreign body reactions and improving long-term dialysis outcomes for patients.
Phenotypeca, Invizius and CPI were awarded an Innovate UK Smart Grant in December 2019: “Development of second-generation Saccharomyces cerevisiae hosts for enhanced protein yield and quality”. This project applies technology proven for the cGMP manufacture of biopharmaceuticals to the production of Invizius’ H-Guard product. Using genetically diverse strains of baker’s yeast, S. cerevisiae, Phenotypeca will screen populations of up to a billion progeny to identify cells with improved properties for H-Guard production during yeast fermentations performed at CPI.
“We have made a great start”, says Keith Williams, Managing Director of Phenotypeca, who is leading the project, “It’s been exceptional to bring together such a unique combination of world-leading scientists to improve our manufacturing technology in this way and all in the UK. This has been made possible by Innovate UK’s support now and during previous infrastructure investments at CPI. We look forward to pressing on with this 18-month project and getting back into the labs soon!”
Phenotypeca Ltd is a synthetic biology company with research facilities in the University of Nottingham’s Biodiscovery Institute, specialising in rapid strain optimisation for the bioprocessing industries. The company uses proven technology, with a long safety track-record, from biopharmaceutical manufacturing, combined with advanced yeast breeding and genomics technologies to improve the phenotypes of yeast cells for industrial processes. The yeast genomics technology was initially developed by Professor Ed Louis at the University of Nottingham and then later at the University of Leicester.
Invizius is a medical device company based in central Scotland, developing solutions to improve dialysis patients’ treatment and prognosis.
Despite significant improvements in haemodialysis’ quality and efficacy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications. With its proprietary H-Guard™ technology, Invizius addresses the side effects of haemodialysis to help patients feel better and suffer fewer cardiovascular complications.
CPI is an independent technology innovation centre and a founding member of the UK Government’s High-Value Manufacturing Catapult. CPI applies its years of experience across a broad range of industries to ensure that every great invention gets the best opportunity to become a successfully marketed product.
CPI’s integrated approach provides its partners with a unique combination of assets, expertise and skills to drive successful innovation. With a deep understanding of innovation processes and funding, outstanding technical expertise and industry-relevant assets, CPI enables products and processes to be quickly and cost-effectively brought to market. By employing bright minds from both academia and industry, CPI helps create a bespoke team that will provide the right support, helping to navigate the route to commercialisation while reducing risk along the way.